NTLA — Intellia Therapeutics, Inc.

—
Nasdaq · Health Care · Life Sciences Tools & Services · CIK 1652130 ·
Last close
$9.78
Market Cap
$1.37B
52W High
$18.48
52W Low
$7.95
ADV30
5,323,407
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 7,163,000 — -122,325,000 -127,485,000 902,560,000 156,098,000 289,471,000
Jun 2026 7,659,000 — -112,760,000 -106,634,000 857,164,000 106,128,000 129,458,000
Mar 2026 15,048,000 — -100,532,000 -96,231,000 758,779,000 134,697,000 137,840,000
Dec 2025 23,017,000 — -98,710,000 -95,786,000 842,127,000 155,464,000 170,733,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-346,643,000
Investing CF
$-48,469,000
Financing CF
$346,519,000
CapEx
$-2,043,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.36
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,792,959,000
Inventory
—
Receivables
$7,321,000
ST Investments
$331,631,000
EBIT TTM
$-423,479,000
Pretax Income TTM
$-399,975,000
Interest Exp TTM
—
Analysts
18

Yahoo Snapshot (yfinance, live)

Total Revenue
$59,506,000
EBITDA
$-414,400,000
Free Cash Flow
$-249,825,376
Enterprise Value
$1,360,610,560
Total Cash
$437,759,008
Total Debt
$73,410,000
Shares Out
140,358,512
Trailing EPS
$-3.35
Book Value
$5.77
ROE
-55.4%
ROA
-30.1%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 67,671,000 -440,990,000 -412,694,000 842,127,000 170,733,000 671,394,000 -394,736,000
Dec 2024 57,877,000 -534,263,000 -519,021,000 1,191,015,000 319,059,000 871,956,000 -348,880,000
Dec 2023 36,275,000 -515,291,000 -481,192,000 1,300,977,000 250,808,000 1,050,169,000 -394,086,000
Dec 2022 52,121,000 -458,164,000 -474,186,000 1,520,114,000 284,530,000 1,235,584,000 -333,287,000

TTM Snapshot

Revenues TTM
$59,506,000
NetIncome TTM
$-399,975,000
OpCashFlow TTM
—
Assets (Latest)
$857,164,000
Forward EPS
$-2.65

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $10.00 · spot: $9.77 · call volume: 214 · put volume: 965
Expected Move to 2027-01-15: ±$2.34 (23.95%) — implied range $7.43 – $12.11 · ATM straddle on $10.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ABSI Absci Corp $1.31B $7.58 —
CLDX Celldex Therapeutics, Inc. $2.20B $28.04 —
NEOG NEOGEN CORP $2.38B $10.90 —
OABI OmniAb, Inc. $736.59M $5.05 —
QDEL QuidelOrtho Corp $677.21M $9.87 —

News headlines (Yahoo Finance, 1h cache)

Intellia Therapeutics (NTLA), Why Is It Back In The Spotlight?
2026-11-17 10:10 · Yahoo
Intellia Therapeutics' One-Time HAE Therapy Cuts Attacks 87% in Trial as FDA Decision Nears
2026-11-12 21:14 · Yahoo
Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026
2026-11-12 15:00 · Yahoo
Intellia Therapeutics to Present at Jefferies Global Healthcare Conference in London
2026-11-10 13:00 · Yahoo
Intellia Therapeutics (NTLA) Stock Could Look Stretched On Phase 3 Trial Progress
2026-11-07 05:20 · Yahoo
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-06 21:05 · Yahoo
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates
2026-11-05 13:35 · Yahoo
Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
2026-11-05 13:00 · Yahoo
Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)
2026-11-04 13:00 · Yahoo
Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations
2026-11-03 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.